Sign In
Buy KTOV
$2.94
+0 (+0%)
At Close: Aug 17, 2022
Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II
12:05pm, Tuesday, 19'th May 2020
TEL AVIV, Israel, May 19, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the positive
Kitov Closes $10 Million Registered Direct Offering
08:00pm, Friday, 08'th May 2020
TEL-AVIV, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion
Kitov Announces $10 million Registered Direct Offering
12:00pm, Wednesday, 06'th May 2020
TEL-AVIV, Israel, May 06, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants
12:05pm, Monday, 20'th Apr 2020
TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasi
18 Healthcare Stocks Moving In Monday's Pre-Market Session
11:35am, Monday, 30'th Mar 2020
Gainers
• Plus Therapeutics, Inc. (NASDAQ:PSTV) stock surged 38.89% to $2 during Monday's pre-market session.
• Owens & Minor, Inc. (NYSE:OMI) stock moved...
Kitov Closes $6.0 Million Public Offering
12:00pm, Tuesday, 17'th Mar 2020
TEL-AVIV, March 17, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr
Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast
12:15pm, Thursday, 12'th Mar 2020
TEL AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas
Kitov Announces Pricing of $6.0 Million Public Offering
12:00pm, Thursday, 12'th Mar 2020
TEL-AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
02:36pm, Wednesday, 26'th Feb 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 25) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) (Cowen
Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers
02:00pm, Monday, 24'th Feb 2020
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced it will expand t
Kitov Pharma Provides Corporate Update and Reports Full-Year 2019 Financial Results
12:00pm, Tuesday, 11'th Feb 2020
TEL AVIV, Israel, Feb. 11, 2020 -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion.
Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24
01:20pm, Monday, 03'rd Feb 2020
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt from the
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt from the
Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
01:35pm, Thursday, 09'th Jan 2020
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that it has appo
